The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|February 14, 2022
Rheumatoid Arthritis Quiz: Management of Fatigue in RA
Author(s)Ingrid Torjesen
Fatigue is commonly experienced by patients with rheumatoid arthritis, so how should patients experiencing it be managed? Take this quiz on managing fatigue in rheumatoid arthritis to test your knowledge.
Advertisement
Use of which of the following medications is mostly likely to be associated with fatigue in patients with rheumatoid arthritis?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement